Introduction
Squamous cell carcinomas of the head and neck (HNSCC) are associated with a history of alcohol and tobacco consumption in the vast majority of patients (Forastiere et al., 2001) . Despite advances in surgery and radiotherapy, the prognosis of HNSCC has not significantly improved over the past 20 years (Forastiere et al., 2001; Tannapfel and Weber, 2001 ). In general, HNSCC often proliferate rapidly, are locally aggressive, and exhibit a high tendency to metastasize to cervical lymph nodes (Forastiere et al., 2001) . Biological research on HNSCC has mainly focused on two different strategies: tumorigenesis and prognosis, that is to identify cellular and molecular mechanisms leading to carcinogenesis of squamous cell epithelia. Furthermore, these efforts helped to define molecular markers for improved therapies and prognosis prediction. Although HNSCC is infiltrated by different immune cells, patients with HNSCC show a profound impairment of cellular immune responses (Song and Grandis, 2000) . The Janus kinase (JAK)/signal transducers and activators of transcription (STAT) signaling plays a significant role in a number of important biological responses, including immune function, cellular growth, differentiation, mast cell development and hematopoiesis (Bowman et al., 2000; Levy and Gilliland, 2000; Shelburne et al., 2003) . The cytokine-inducible SH2-domain-containing protein (CIS) and suppressors of cytokine signaling 1-7 (SOCS-1-7) have been identified in the SOCS family to date (Cacalano et al., 2001; Larsen and Ro¨pke, 2002) . SOCS family members have distinct mechanisms of inhibiting JAK/STAT signaling (Yoshikawa et al., 2001; Melzner and Mo¨ller, 2003) . SOCS-1 is believed to inhibit signaling through direct interaction with JAK (Yoshikawa et al., 2001) . SOCS-3 can bind both the cytokine receptor and JAK and is recruited to the tyrosine-phosphorylated receptor, facilitating the inhibition of JAK (Cacalano et al., 2001 ). Another possible mechanism by which SOCS proteins restrict signaling is to promote protein degradation (Ali et al., 2003) .
It has been reported that abnormalities of the JAK/ STAT pathway are associated with cancer (Sengupta et al., 1998; Niu et al., 1999; Grandis et al., 2000; Sriuranpong et al., 2003) . For example, activation of STAT3 correlates with cell proliferation in HNSCC (Sriuranpong et al., 2003) and malignant melanoma (Niu et al., 1999) . Inhibition of JAK/STAT signaling results in suppression of cancer cell growth and induces apoptosis in various cancer types (De Vos et al., 2000; Mora et al., 2002) .
Aberrant hypermethylation of CpG islands in promoter regions has been shown to be associated with transcriptional silencing of various genes in several types of cancer (Esteller 2002; Herman and Baylin, 2003; Lin et al., 2004) . Recently, SOCS-1 was found to be frequently silenced by hypermethylation in hepatocellular carcinoma (HCC) (Yoshikawa et al., 2001) , pancreatic carcinoma (Fukushima et al., 2003) , and hepatoblastomas . SOCS-1 appears to have tumor suppressor activity, since restoration of the SOCS-1 gene expression in HCC cells caused growth suppression and induction of apoptosis (Yoshikawa et al., 2001) . Likewise, silencing of SOCS-3 by promoter methylation in human lung cancer has recently been reported (He et al., 2003) .
Therefore, in the present study, we analysed the status of SOCS-1 and SOCS-3 in HNSCC and its precursor lesions to elucidate a possible role of these genes in the carcinogenesis of HNSCC.
Results
SOCS-3 and SOCS-1 expression was first analysed in four HNSCC cell lines. SOCS-3 transcripts was absent or dramatically decreased in three cell lines from oral as well as tongue squamous cell carcinomas (CAL-27, HN and BHY cells) (Figure 1a ). In contrast, SOCS-3 expression was detectable in all normal controls, including primary cell cultures ('NSC' normal squamous epithelial cells (Figure 1a) ), PBMC of healthy donors, as well as in CAL-33 tumor cells (Figure 1a ). SOCS-1 was expressed in normal epithelial cells (NSC), PBMCs of normal donors, in tonsils, CAL-27 as well as in BHY and HN cells. In contrast to SOCS-3, SOCS-1 mRNA transcripts were absent in CAL-33 cells (Figure 1a) .
To identify the underlying mechanism of the lack of transcripts, the CpG islands of the SOCS-1 and SOCS-3 promoters were analysed. Methylation-specific PCR (MSP) revealed, that in those cell lines with undetectable SOCS-3 transcripts (CAL-27, BHY and HN), promoter methylation occurred (Figure 1b) . In those cells with visible SOCS-3 transcripts, no methylated bands were observed. MSP for SOCS-1 exhibited promoter methylation only for CAL-33 cells, the cell line with absent SOCS-1 transcripts (Figure 1a and b) .
We also used bisulfite sequencing to analyse details of the methylation status of CpG sites of the SOCS-3 and the SOCS-1 promoter regions. Consistent with MSP results, we found that the SOCS-3 CpG islands in HN as well as CAL-27, but not in CAL-33 cell lines, were heavily methylated ( Figure 1c ). Heavy methylation of the SOCS-1 promoter was detected in CAL-33, but not in BHY and HN cells (Figure 1d ).
To confirm that promoter hypermethylation was responsible for the lack of SOCS-3 as well as SOCS-1 expression in the cell lines tested, the effect of 5-AZA-DC, a drug that inhibits DNA methylation, was analysed. After exposure of the SOCS-3 nonexpressors HN and CAL-27 to 5-AZA-DC for 3 days, reexpression of SOCS-3 was detected (Figure 2a ) with little or no change in the expression of the housekeeping gene GAPDH. The treatment of the SOCS-1 nonexpressor CAL-33 also exhibited a re-expression after demethylation treatment (Figure 2b) .
To assess the status of the SOCS-3 promoter region in vivo, 94 HNSCC samples and corresponding normal mucosa were analysed after microdissection (Figure 3) . Of 94 samples, 85 (90%) showed decreased or even absent mRNA expression for SOCS-3, as indicated by RT-PCR (data not shown; Table 1 ). Consistent with this, we found aberrant methylation in these 85 tumor samples by MSP but not in their matched normal tissue samples ( Figure 4 and Table 1 ). In high-grade dysplastic epithelium, we found SOCS-3 methylation in 10/16 cases (63%) and in 9/21 cases (43%) of low-grade dysplasia, respectively.
The methylation status of the SOCS-1 promoter region was also examined in 94 HNSCC specimens and corresponding normal mucosa tissues. Aberrant BHY and HN) . Bands (134 bp for SOCS-3 and 184 bp for SOCS-1, respectively) in lanes labeled 'U' represent unmethylated DNA products amplified with npn-methylationspecific primers. Bands in lanes labeled 'M' refer to methylated DNA products amplified with methylation-specific primers (134 and 183 bp, respectively). L ¼ DNA ladder. (c and d) Bisulfite-sequencing analysis of cell lines. Open and filled squares represent unmethylated and methylated CpG islands, respectively. We sequenced five clones of PCR products amplified from bisulfite-treated genomic DNA for each cell line. HN and CAL-27 exhibited heavily methylated CpG islands of . Methylation of the SOCS-1 gene was examined with three primer sets. CAL-33 exhibited a heavily methylated promoter region, whereas BHY and HN lacked methylation (d) methylation of the SOCS-1 promoter and reduced mRNA transcripts were detected in 10/94 (11%) of the specimens (Table 1) . In most cases, unmethylated bands (U) were also visible in the tumor tissue, which may result from admixed normal cells within the tumor specimens (e.g. granulocytes, fibroblasts). In corresponding non-neoplastic mucosa, we failed to detect methylated SOCS-1. SOCS-1 methylation was observed in 2/16 cases (13%) of high-grade and in 1/21 samples (5%) of low-grade dysplasia. In one case (pt #87), SOCS-1 as well as SOCS-3 were methylated. This patient also had lymph node metastases, which exhibited methylated SOCS-1 and SOCS-3 promoters ( Figure 5 ). We also examined corresponding lymph node metastases, which were available from 15 cases. All metastases exhibited the same methylation status of the SOCS-1 and SOCS-3 promoters like their respective primary tumors (data not shown).
On the protein level, SOCS-1 and SOCS-3 were detected in 84 of 94 and 18 of 94 tumors, respectively ( Figure 6 and Table 1 ). All of the 84 SOCS-1-positive tumors contained unmethylated SOCS-1 promoter while SOCS-3 protein was detected in nine specimens with a methylated SOCS-3 promoter. Protein expression was absent in high-grade dysplasias, which contained a methylated SOCS-3 promoter ( Figure 6 ). In contrast, SOCS-1 and SOCS-3 positivity occurred regularly in inflammatory cells within the tumor or in its periphery ( Figure 6 ). To analyse whether restoration of SOCS-3 resulted in growth suppression, CAL-27 cells were transfected (n ¼ 4; transfection efficiency E27%; as assessed by GFP staining) with an internal ribosome entry site (IRES) construct of wild-type SOCS-3 and enhanced GFP. After transfection, a significant decrease in cell numbers was observed in the CAL-27 cells transfected with SOCS-3 (14% alive cells vs 82% in empty vectortransfected cells) (Figure 7a ). BrdU staining revealed 59 vs 17.5% labeled cells transfected with vector control as compared with SOCS-3-transfected cells, respectively (Figure 7b and c) . Likewise, MIB-1 staining of the proliferation-associated nuclear antigen showed significant reduction of proliferating cells upon overexpressing SOCS-3 wild-type (Figure 7d ). The annexin-V apoptosis assay showed a significantly higher rate of apoptotic cells in SOCS-3-transfected cells as compared to vector control (52 vs 8%, respectively; Figure 7e ).
Finally, Western blot analysis was used to analyse the STAT-3 pathway. Transfection of CAL-27 cells with SOCS-3 led to detectable SOCS-3 protein (Figure 7f 
Discussion
The protein families of SOCS-1-7, also known as STAT-induced STAT inhibitors (SSIs), are members of cytokine-inducible negative regulators of cytokine signaling (Larsen and Ro¨pke, 2002) . Expression of SOCS proteins was found to be rapidly up-regulated by IL-6 (CIS, SOCS-1-3) (Niu et al., 1999) , LIF (CIS, SOCS-1-3), IL-11 (SOCS-3) and OSM (CIS, SOCS-1 and SOCS-3) (Larsen and Ro¨pke, 2002) . The proteins function downstream of cytokine receptors and take part in a negative feedback loop to attenuate cytokine signaling. There is increasing evidence that perturbances in STAT/SOCS proteins are involved in the pathogenesis of certain human malignancies (Niu et al., 1999; Grandis et al., 2000; Yoshikawa et al., 2001; Nagai et al., 2002; Fukushima et al., 2003; Galm et al., 2003; Nagai et al., 2003; Sriuranpong et al., 2003) . Moreover, cancer-related defective JAK/STAT/ SOCS pathways may negatively affect tumor response to cytokine-based immunotherapies and innate immunity, as has been recently demonstrated (Wang et al., 2004) . Aberrant hypermethylation of promoter regions that silence gene transcription has been recognized as a mechanism for inactivating tumor suppressor genes in cancer.
We report that inactivation of SOCS-3 is frequently observed in HNSCC mainly due to promoter hypermethylation. Recently, hypermethylation of the SOCS-1 gene was reported in hepatocellular and pancreatic cancers as well as in multiple myeloma (Yoshikawa et Galm et al., 2003) . On the other hand, SOCS-3 inhibits STAT-3 phosphorylation by binding next to JAK sites on cytokine receptors (Cacalano et al., 2001) . A mechanism for the involvement of SOCS-3 in human cancers has been recently reported by He et al. (2003) . In lung cancer, SOCS-3 functions as a growth suppressor and inducer of apoptosis (He et al., 2003) . In the present study, we found that frequent hypermethylation of the functional SOCS-3 promoter region was correlated with silencing of the SOCS-3 gene in HNSCC samples. In contrast, normal cells that expressed SOCS-3 showed a functionally active promoter. SOCS-3 expression was restored in cell lines treated with 5-AZA-DC. In lowand high-grade dysplastic squamous epithelium, SOCS-3 was also methylated showing increasing rates of methylation with higher grades of dysplasia. Taken together, our results suggest that SOCS-3 silencing results from promoter methylation and may represent an important cause of constitutive activation of the JAK/STAT pathway in HNSCC. It may also act as an important epigenetic event during HNSCC carcinogenesis, since we also observed SOCS-3 inactivation in dysplastic epithelium.
According to our data, restoration of SOCS-3 results in growth suppression and induction of apoptosis. The factors responsible for these effects remain only partly elucidated. Our results show decreased phosphorylation of STAT-3 and a decrease of Bcl-2 and Bcl-x L in SOCS-3-expressing relative to control-transfected cells which may likely contribute to the higher level of apoptosis seen in these experiments. Interestingly, the magnitude of suppression was higher than the transfection efficiency (82 vs 27%) which may be explained by the secretion of a soluble proapoptotic factor. It has been described that inhibition of STAT-3 signaling through a dominant-negative STAT-3 mutant led to detectable levels of the apoptosis-inducing factor TRAIL in mouse B16 melanoma cells (Niu et al., 2001) . Therefore, we measured TRAIL protein as well as its effect of cellular supernatants of SOCS-3-transfected cells on untreated CAL-27 cells, but we neither found TRAIL expression nor any differences in cell proliferation. Further studies are warranted to identify the responsible mechanism of apoptosis induction.
In contrast to SOCS-3, SOCS-1 was only infrequently silenced in HNSCC and its precursor lesions. It has been shown that in HCC, methylation of SOCS-1 occurred in about 65% (Yoshikawa et al., 2001) . In HCC cells, SOCS-1 is silenced by methylation and is unable to terminate the causative signal leading to JAK activation and constitutive signaling. As a result, SOCS-1-silenced cells showed unrestricted growth through the JAK/ STAT pathway. The specific factors and proteins that stimulate the JAK/STAT pathway have not yet been identified in squamous cancer cells, but various cytokines, growth factors and hormones are known to act as stimulators of this pathway (Yoshikawa et al., 2001 ). In addition, activation of target genes such as c-fos, c-myc, Bcl-2 and Bcl-x occurs through the JAK/STAT pathway (Bowman et al., 2000) .
Therefore, the phenomenon of SOCS-3, and to a lesser extent SOCS-1, silencing as a result of promoter methylation may represent a common event during HNSCC carcinogenesis. SOCS-3 itself may potentially function as an important tumor suppressor gene (Yoshikawa et al., 2001) . The high prevalence of SOCS-3 promoter hypermethylation also supports targeted therapies of the JAK/STAT pathway. Future work defining the role of the JAK/STAT pathway in the development of HNSCC should focus on specific stimulatory factors and downstream targets.
Materials and methods

Patients and tissue samples
Tissue samples of 94 patients with HNSCC were collected between February 1995 and February 2002, with the longest observation period being 7 years. Tumor typing and staging was performed using WHO (2000) and UICC (2002) . The majority of the primary tumors were located in the oropharynx (37 cases), followed by larynx (26 cases), In 15 patients, corresponding lymph node metastases (pN1) were available for analysis.
As a control group, randomly selected peripheral blood mononuclear cells (PBMC) from 20 healthy volunteers of the same geographical area (median age 49 years; 12 males, eight females) were used .
Dysplasia
A total of 37 samples of squamous cell dysplasia (n ¼ 21, low and n ¼ 16, high grade, respectively) were obtained from patients without invasive cancer and diagnosed by two independent pathologists blinded to clinical data according to the WHO criteria (WHO, 2000) .
All patients were informed of special examination of tumor samples which was in accordance with the ethical standards of the Committee on Human Experimentation of the University of Leipzig. All samples were obtained during treatment procedures with therapeutical intent.
Cell lines
Squamous cell carcinoma cell lines (BHY, HN, and CAL-33) and normal lung fibroblasts (CCL-75 cells) and the squamous cell carcinoma cell line CAL-27 were obtained from the American Type Culture Collection (ATCC, Rockville, MD, USA) and from the DSMZ (Braunschweig, Germany), respectively. All cell lines were grown in RPMI 1640 medium or Dulbecco (Gibco BRL, Gaithersburg, MD, USA) supplemented with 10% fetal bovine serum (FBS) (Gibco BRL). All cell lines were kept at 371C in a humidified incubator with 5% CO 2 in air.
Microdissection and sample processing
For each tumor sample, the histopathological lesions of interest were first identified on routinely stained frozen sections, as described before (Weber et al., 2003) . Sections measuring 12 mm cut from frozen tissue blocks were mounted on glass slides with a thickness of 0.17 mm (very thin glass slides are needed to prevent laser energy from being dispersed before reaching the tissue section). An ultraviolet laser microscope system was then used to isolate particular cell populations (UV-laser microbeam; PALM, Bernried, Germany. The pulsed UV laser of high beam quality (nitrogen laser, wavelength 337 nm, maximum frequency 20 pulses/s, pulse duration 3 ns) was combined with an inverse microscope and focused through an objective of high numerical aperture into the tissue plane. The beam spot diameter measured approximately 0.3-0.5 mm. As a result of the extremely high-energy density within the focal point (laser energy at object plane approximately 5 mJ), all biologic material is destroyed. Using the UV laser beam at a high repetition rate (approximately 20 pulses/s), a circle was cut around the target cells (Figure 3a, b, d and e) . This resulted in complete separation of the target population from neighboring tissues (Figure 3c and f) . The approximate number of cells was estimated to be at least 1000 per sample for PCR analysis. After microdissection, the tissue samples were then put into Eppendorf tubes and standard methods for DNA and RNA extraction were used (Weber et al., 2003) .
Methylation analysis
After microdissection (Weber et al., 2003) , MSP was applied to investigate the methylation status of the promoter regions of the SOCS-1 and SOCS-3 genes. After an initial bisulfite treatment to modify the DNA, PCR was performed to distinguish methylated from unmethylated DNA as described by Herman et al. (1996) . Briefly, 2 mg of genomic DNA were denatured with 0.3 M NaOH. In all, 10 mM hydroquinone and 3 M sodium bisulfite were added and incubated at 501C for 16 h. Afterwards, modified DNA was purified using the Wizard DNA purification resin (Qiagen, Hilden, Germany) followed by desulpfhonating in 0.3 M NaOH and subsequent ethanol precipitation and resuspension in 30-50 ml water. MSP was performed using specific primers and conditions previously described (Herman et al., 1996) . Briefly, a 20 ml reaction volume containing 150 ng bisulfite modified DNA, 1 Â PCR buffer, 1.5 mM MgCl 2 , 0.16 mM dNTPs, 0.25 mM specific primer mix (forward and reverse primers; Table 2 ) and 1 unit Taq enzyme (Roche s ) was used. The primers were designed according to a previously published protocol and adopted to the specific conditions of HNSCC (He et al., 2003 , Table 2 ).
The PCR products were electrophoresed on a 2% agarose gel, stained with ethidium bromide and visualized under UV illumination. Placental DNA treated with methyltransferase was used as a positive control for methylation.
Bisulfite sequencing for SOCS-3 and SOCS-1
Bisulfite-treated genomic DNA was amplified by using primers (5 0 -GTG-TAG-AGT-AGT-GAT-TAA-ATA-3 0 (forward) and 5 0 -TCC-TTA-AAA-CTA-AAC-CCC-CTC-3 0 (reverse)) designed to amplify nucleotides À1084 to À671 of the SOCS-3 promoter region (the start codon ATG of SOCS-3 is defined as þ 1), adopting the protocols published recently by He et al. (2003) . For SOCS-1, three sets of primers were used (Yoshikawa et al., 2001; Uehara et al., 2003; Oshimo et al., 2004) . Primers for region 1 were 5-GAG GAG GGA GGG GAG TTT AGG GTA GTT-3 (sense) and 5-TTC AAC CTC AAT AAA CAC AAC TAA AAA A-3 (antisense). Primers for region 2 were 5-TTT TTT AGT TGT GTT TAT TGA GGT TGA A-3 (sense) and 5-CCA CCT AAT TAT ATA CTA CCA TCC TAC AA-3 (antisense). Primers for region 3 were 5-TGT AGG ATG GTA GTA TAT AAT TAG GTG GT-3 (sense) and 5-TAA TAC TCC AAC AAC TCT AAA AAA CAA TC-3 (antisense).
The PCR products were cloned into Topo TA cloning kit (Invitrogen, Carlsbad, CA, USA). Five randomly picked clones were sequenced on an ABI PRISM 3100 Genetic Analyzer (Applied Biosystems, Foster City, CA, USA). 
RT-PCR
The presence of SOCS-3 mRNA transcripts was analysed by semiquantitative PCR (LightCycler, Roche s ). In all, 200 ng of RNA extracted from 30 mg fresh frozen tissue sample using the RNeasy Mini kit (Qiagen s , Hilden, Germany) were reverse transcribed with the primer sequences for a 579-bp fragment of the human SOCS-3 cDNA (5 0 -TTC TAC TGG AGC GCA GTG AC-3 0 (forward) and 5 0 -ACT GGG TCT TGA CGC TGA G-3 0 (reverse)) in 20 ml of RT-mix with a QuantiTect SYBR Green RT-PCR kit (QIAGEN s GmbH, Hilden, Germany) in accordance with the manufacturer's instructions.
Demethylation
To induce expression of SOCS-3 after exposure to 5-aza-2-deoxycytidine (5-AZA-DC), a drug that inhibits DNA methylation, subconfluent cultures of the SOCS-3 nonexpressing squamous cancer cell lines (CAL-27, HN) were exposed to 1 mM 5-AZA-DC for 4 days. After isolation of total RNA using the RNeasy extraction kit (QIAGEN s GmbH, Hilden, Germany), multiplex RT-PCR was performed for SOCS-3 as described above.
Transient transfection, proliferation, apoptosis and STAT-3 protein analysis
The human squamous cell carcinoma cell line CAL-27 (ACC 446) was obtained from the German Collection of Microorganisms and Cell Cultures (DSMZ Braunschweig, Germany). Cell lines were maintained in Dulbecco's MEM supplemented with 10% fetal bovine serum, penicillin (100 U/ml) and streptomycin (100 mg/ml). All cells were cultured at 371C in a humid incubator with 5% CO 2 .
The backbone vector pcDNA3.1zeo (Invitrogen s ) was used to construct the pcDNA3.1zeo-IRES-EGFP. Starting from a retroviral vector containing ECMV IRES and EGFP (kindly provided by Dr Moritz and Dr Flasshove, Essen, Germany) IRES-GFP was PCR amplified using the primers 5-GGGTCGACATCCGCCCCTCTCCCTCCCC-3 and 5-GGGCGGCCGCTTACTTGTACAGCTCGTCCATGC-3 yielding a 1331 bp product. The SalI and NotI restriction sites included in these primers were used to unidirectionally ligate the PCR-product into SalI/NotI cut pcDNA3.1zeo resulting in pcDNA3.1zeo-IRES-EGFP. The SOCS3 open reading frame and the Kozak site were PCR amplified from human kidney total RNA (Invitrogen s ) using the primers 5-GCTCCGTGCGCCATGGTC-3 and 5-GCTTTAAGGGG TAAAGGGCG-3 yielding a 703 bp product. The SOCS-3 cDNA was ligated into pCR2.1Topo (Invitrogen s ). An EcoRI fragment containing the SOCS-3 cDNA from the pCR2.1 vector was ligated into EcoRI-linearized pcDNA3.1-IRES-EGFP resulting in pcDNA-SOCS3-IRES-EGFP. The GFP control vector was constructed in analogy by PCR amplifying the EGFP open reading frame with the primers 5-AC CATGGTGAGCAAGGGCGAG-3 and 5-GCATGGAC GAGCTGTACAAGTAA-3. The 720 bp product was cloned into pCR2.1Topo, cut out with EcoRI and ligated into the EcoRI-linearized pcDNA3.1zeo. Vector orientation of the inserts was checked by PCR and sequencing. For transfection, the cells were seeded in six-well plates 24 h before transfection. Effectene transfection reagent (Qiagen s ) was used to mediate transfection by using 1 mg per well of control vector or the indicated amounts of the expression plasmid (pcDNA3.1zeo-SOCS3-IRES-eGFP (0.2, 0.5 and 1.0 mg) per well, respectively). The transfection procedure was carried out according to the manufacturer's instructions. All transfection experiments were repeated three times.
Cell proliferation and viability was measured using the BrdU Labeling and Detection Kit I (Roche s , Cat # 1296736). To analyse the proliferative activity on the morphological basis, immunostaining of MIB-1 [Ki67] was performed. Apoptosis was analysed using the Annexin V FITC Apoptosis Detection Kit (Oncogene Science s ) and analysed by flow cytometry. Necrotic cells exhibit membrane permeabilization and will also bind Annexin V-FITC, but propidium iodide is used to distinguish between viable, early apoptotic and necrotic or late apoptotic cells. Propidium iodide is excluded from viable (FITC-negative) and early apoptotic (FITC-positive) cells. Late apoptotic cells will stain with both FITC and propidium iodide due to the final disintegration of the cell.
Western blot for protein analysis of STAT-3, Bcl-2, Bcl-xL and SOCS-3 was performed as recently described (Weber et al., 2003) . Protein levels of phosphorylated STAT-3 were analysed using the phospho-STAT3 (Tyr705) antibody (Cell Signaling s Technology, Beverly, USA; Cat.# 9138) at a dilution of 1 : 800. SOCS-3 protein was analysed using a rabbit polyclonal antibody at a concentration of 1 : 1000 (Fusions Antibodies s , Belfast Northern Ireland, GB; Cat.# FA1017). Bcl-2 as well as Bcl-xL proteins were analysed using monoclonal antibodies for Bcl-2 (Cell Signaling s Technology, Beverly, USA; Cat.# 2872, dilution 1 : 800) and for Bcl-xL (Cell Signaling s Technology, Beverly, USA; Cat.# 2762; dilution 1 : 200).
Abbreviations HNSCC, head and neck squamous cell carcinoma; SOCS, suppressor of cytokine signaling; STAT, signal transducer and activator of transcription; JAK, Janus kinase.
